Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
$1.78M
Mr. Stephan Jackman
4.00
Atlanta, GA
Jun 15, 2021
-0.01
$-147.00
0.12
0.14
-13,070.22%
-0.15
-0.00
-0.58
24.21
0.14
-1,575.04%
415.21%
Similar stocks (12)
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Alector, Inc.
ALEC
Solid Biosciences Inc.
SLDB
Inozyme Pharma, Inc.
INZY
HOOKIPA Pharma Inc.
HOOK
Adverum Biotechnologies, Inc.
ADVM
Acumen Pharmaceuticals, Inc.
ABOS
X4 Pharmaceuticals, Inc.
XFOR
Kezar Life Sciences, Inc.
KZR
Senti Biosciences, Inc.
SNTI
TRACON Pharmaceuticals, Inc.
TCON
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (12)
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Alector, Inc.
ALEC
Solid Biosciences Inc.
SLDB
Inozyme Pharma, Inc.
INZY
HOOKIPA Pharma Inc.
HOOK
Adverum Biotechnologies, Inc.
ADVM
Acumen Pharmaceuticals, Inc.
ABOS
X4 Pharmaceuticals, Inc.
XFOR
Kezar Life Sciences, Inc.
KZR
Senti Biosciences, Inc.
SNTI
TRACON Pharmaceuticals, Inc.
TCON
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%